Andrzej Czarnecki MD, PhD, DSc, FFPM, FISPE is currently the Director and Deputy EU QPPV at Eli Lilly. Dr Czarnecki has a distinguished career in pharmacology, regulation and pharmacovigilance in academia, regulatory authorities and industry, and as a consultant to public bodies e.g. WHO and EU Commission and to several governments. He is a prolific contributor to professional and scientific activities related to areas of his expertise and he contributes to the development of medicines policy internationally. After graduation Dr Czarnecki worked in cardiovascular medicine and research in Warsaw and subsequently in the UK at the Royal Postgraduate Medical School in London, University of Cambridge, as well as in the Medicines Control Agency. Andrzej has been involved in educational activities for pre- and postgraduate students at several Universities in the EU. He was a Professor of Pharmacoepidemiology in Warsaw and head of Pharmacovigilance and Clinical Trials Departments. He authored over 120 papers. He was elected a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) in the UK and of the International Society of Pharmacoepidemiology (FISPE). Andrzej has been an active member of the DIA since 1992, He served as a EuroMeeting chair, member of Committees, chair of tracks, workshops, courses and sessions and frequently as a speaker. From 2009 Andrzej was the Editor-in-Chief of the DIA Global Forum. In 2004 he received the ‘Outstanding Services Award’.